Emcure

Ref: EPL/CS/SE/0097/2025 **Date:** December 23, 2025

To,

National Stock Exchange of India Limited **Exchange Plaza, C-1, Block G,** **Bandra Kurla Complex, Bandra (East),** **Mumbai – 400 051** **Script Symbol: EMCURE**	**BSE Limited** **P J Towers,** **Dalal Street,** **Mumbai - 400 001** **Scrip Code/Symbol: 544210/ EMCURE**

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") – Update on US FDA inspection at our manufacturing facility located at Kadu, Surendranagar, Gujarat, India.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our intimation dated October 10, 2025, on the inspection conducted by the United States Food and Drug Administration ("US FDA") at our manufacturing facility located at Survey No. 485 (New), 160/P1 (Old), Kadu, Taluka - Lakhtar, Surendranagar - 382775, Gujarat, we wish to inform you that the Company has received Establishment Inspection Report (EIR). The US FDA has classified the inspection of the facility as "No Action Indicated" (NAI).

You are requested to take the above information on your records.

Thanking you,

For **Emcure Pharmaceuticals Limited**

TAJUDDIN SABIR SHAIKH
Digitally signed by TAJUDDIN SABIR SHAIKH
Date: 2025.12.23 17:47:45 +05'30'

Tajuddin Shaikh
Chief Financial Officer